HighTower Advisors
NBIX icon

HighTower Advisors’s Neurocrine Biosciences NBIX Stock Holding History

HighTower Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$2K – 2467
2019
Q1 		$2K Buy
+300
New +$25.1K ﹤0.01% 2253

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HighTower Advisors's NBIX Position: Q2 2026 in Review

HighTower Advisors reduced its Neurocrine Biosciences (NBIX) stake by 27% in Q2 2026, selling an estimated $444K and leaving 8,205 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2026.

HighTower Advisors first reported a position in NBIX in Q4 2017 and has held it in 35 quarters since. The position peaked at $4.07M in Q2 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • HighTower Advisors held 8,205 shares of Neurocrine Biosciences worth $1.38M as of Q2 2026.
  • HighTower Advisors sold 2,993 Neurocrine Biosciences shares in Q2 2026, an estimated $444K.
  • Neurocrine Biosciences made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2026 holding.
  • HighTower Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 35 quarters since.
  • HighTower Advisors's Neurocrine Biosciences position peaked at $4.07M in Q2 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.